Oncolytics Biotech, Phase Ia/Ib Combination REOLYSIN® and Radiation Clinical Trial

September 28, 2007 - Oncolytics Biotech Inc. (“Oncolytics”) (TSX:ONC, NASDAQ:ONCY) announced that an oral presentation covering interim results from a U.K. Phase Ia/Ib combination REOLYSIN® and radiation clinical trial for patients with advanced or metastatic cancers is scheduled to be presented at the National Cancer Research Institute (NCRI) conference on October 2, 2007 in Birmingham, U.K...Of the six patients who have completed the study to date, three patients (colorectal, melanoma and lung cancer) experienced tumour regression in the target tumour, as well as stable disease in non-treated tumours... Oncolytics Biotech's Press Release -

Gene Express, Lung Cancer Diagnostic

September 27, 2007) - Gene Express, Inc. today announced that its molecular diagnostic test for lung cancer has demonstrated high levels of accuracy in a recent study presented at the American Association for Cancer Research's second International Conference on Molecular Diagnostics in Cancer Therapeutic Development... To determine which genes are active in lung cancer, Dr. Willey and his colleagues utilized Gene Express's proprietary and patented StaRT-PCR™ (Standardized Reverse Transcription Polymerase Chain Reaction) platform technology for measuring messenger RNA (mRNA) transcripts levels of the 15 genes... Gene Express' press Release -

The SFDA of the PRC Grants Immtech Fast Track Status

September 27, 2007 - Immtech Pharmaceuticals, Inc. (AMEX:IMM) announced that the State Food and Drug Administration of the People’s Republic of China (SFDA) has granted Immtech’s application Fast Track Status for conducting a Phase III clinical trial with pafuramidine, the Company’s oral drug candidate for the treatment of Pneumocystis pneumonia (PCP)... Immtech's Press Rease [PDF] -

Spiration, U.S. Pivotal Trial of Minimally Invasive Treatment for Severe Emphysema

Sept. 26, 2007 – Spiration, Inc., a developer of novel medical technology designed to benefit patients with acute and chronic conditions of the lung, today announced that the first patients have been enrolled in the company’s IBV Valve Trial in the United States. The purpose of the trial is to generate safety and effectiveness data for submission to the U.S. Food and Drug Administration (FDA) for approval to market the company’s IBV Valve System in the United States for the treatment of patients with severe emphysema... Spiration's Press Release [PDF] -

Alkermes and Indevus, Positive Results from Phase 2a Clinical Study of ALKS 27 for the Treatment of COPD

September 26, 2007 – Alkermes, Inc. (NASDAQ: ALKS) and Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV) announced positive preliminary results from a randomized, double-blind, placebo controlled phase 2a clinical study of ALKS 27 in patients with chronic obstructive pulmonary disease (COPD).
Alkermes' Press Release -
Indevus' Press Release -

Curis , Development Candidate CUDC-101 and Its Targeted Cancer Drug Development Platform

Sept. 25, 2007--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop proprietary targeted medicines primarily for cancer treatment, provided an update on CUDC-101 and other preclinical drug candidates under its Targeted Cancer Drug Development Platform... CUDC-101 displays anti-proliferation and apoptosis, or programmed cell death, inducing activities in vitro against a broad range of cancer cell types including lung, breast, prostate, colon, liver and pancreas... Curis' Press Release -

Inspired Technologies, FDA 510(k) Approval for the VIAspire Liquefier, Home liquid oxygen

Sept. 25, 2007 - Inspired Technologies, Inc., an innovative respiratory device company, announced it has obtained FDA 510(k) approval for its VIAspire™ Liquefier. The VIAspire Liquefier makes liquid oxygen in the home for patients requiring oxygen therapy, such as those
with Chronic Obstructive Pulmonary Disease (COPD)... Inspired Technologies' Press Release [PDF] -

Pharmacopeia , Phase 1 Clinical Trials of a potential treatment for respiratory disease

Sep 25, 2007 -Pharmacopeia (NASDAQ: PCOP), an innovator in the discovery and development of novel small molecule therapeutics, announced that Schering-Plough has initiated a Phase 1 clinical trial in the United States with PS948115, a compound identified from the collaboration between the two companies. The compound is being evaluated as a potential treatment for respiratory disease... Pharmacopeia's Press Release -

Cell Therapeutics, Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer

Sept. 24, 2007 - Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) has begun a confirmatory phase III clinical trial of combination chemotherapy for women with advanced non-small cell lung cancer (NSCLC) -- the most lethal cancer facing women today. The trial, known as PGT307, will focus exclusively on women with pre-menopausal estrogen levels -- a group whose survival is significantly shorter than post-menopausal women. XYOTAX (TM) (paclitaxel poliglumex) will be studied in combination with carboplatin versus paclitaxel/carboplatin in female NSCLC patients with performance status of 0, 1, or 2... Cell Therapeutics' Press Release -

Encysive Pharmaceuticals, Phase III Study With Thelin (Sitaxsentan Sodium) in Pulmonary Arterial Hypertension

Sep 24, 2007 - Encysive Pharmaceuticals Inc. (Nasdaq:ENCY) will move forward with plans to conduct an additional Phase III study evaluating Thelin(tm) (sitaxsentan sodium) in patients with Pulmonary Arterial Hypertension (PAH)... Encysive Pharmaceuticals's Press Release -

Progen , PI-88 Phase 2 Lung Cancer Results

Sept. 24, 2007 - Progen Pharmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) : the Phase 2 trial administering 250mg of PI-88 in combination with the chemotherapeutic agent docetaxel to patients with advanced non small cell lung cancer did not meet its primary endpoint of significantly improving the progression-free rate at six months compared to docetaxel alone. The trial also did not meet its secondary endpoints of improvement in time to progression, response rate, overall survival and quality of life measures... Progen's Press release [PDF] -

ImClone , Expands IMC-A12 Development with Ten New Planned Clinical Trials

Sept. 20, 2007--ImClone Systems Incorporated (NASDAQ: IMCL) announced that the Cancer Therapy Evaluation Program (CTEP) of the Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI), has selected 10 proposals for Phase I/II clinical trials of ImClone Systems' anti-insulin-like growth factor-1 receptor (IGR-IR) monoclonal antibody known as IMC-A12...Both randomized and nonrandomized Phase II trials sponsored by CTEP will explore the clinical activity, pharmacology and biological effects of IMC-A12 as a single agent or combined with other relevant anticancer agents in a wide range of malignancies including breast, lung, pancreas and liver cancers, as well as both adult and pediatric sarcomas... ImClone's Press Release -

Lilly, ALIMTA® (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer submitted in Europe

Sept 20, 2007 /- Eli Lilly and Company (NYSE: LLY) announced that it has submitted an application with the European Medicines Agency (EMEA) for centralised review of ALIMTA® (pemetrexed for injection), in combination with cisplatin, for the first-line treatment of advanced non-small cell lung cancer (NSCLC)... Lilly's Press Release -

Nymox Saliva Test, Saliva NicAlert, test for tobacco exposure in a family practice setting

Sept 18, 2007 - -Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce the new publication of an independent study reporting positive data on the accuracy and usefulness of the Company's Saliva NicAlert(TM) test for tobacco exposure in a family practice setting. .. Nymox's Press Release -

OSI Pharmaceuticals, Patent Term Extension for Tarceva(R) (erlotinib)

Sept. 18, 2007--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced that the Company has received Notice of Final Determination from the US Patent and Trademark Office that the patent for Tarceva(R) (erlotinib), US Patent No. 5,747,498, covering composition of matter, processes for its preparation, methods of treating cancer, and pharmaceutical compositions containing Tarceva has been extended through November 8, 2018. In addition to the composition of matter patent, OSI also has a crystalline polymorph patent (US Patent No. 6,900,221) for Tarceva which expires in 2020... OSI Pharmaceuticals' Press Release -

LigoCyte , to develop therapies targeting CD103 for the treatment of chronic inflammatory diseases including potential respiratory

September 18, 2007 – LigoCyte Pharmaceuticals, Inc., announced a strategic partnership with Biogen Idec (NASDAQ: BIIB) to develop therapies targeting CD103 for the treatment of chronic inflammatory diseases including potential respiratory, gastrointestinal, and autoimmune indications. CD103 [PDF] is the unique alphaE-beta7 integrin that has been implicated in the activation, homing and retention of lymphocytes that mediate inflammatory diseases affecting mucosal regions of the intestine, skin, and lungs... LigoCyte's Press Release -

Forest Laboratories, single doses of inhaled aclidinium produced a significant bronchodilatory response in 17 patients with COPD

Sept. 18, 2007 - Forest Laboratories (NYSE: FRX) announced today that single doses of inhaled aclidinium produced a significant bronchodilatory response in 17 patients with COPD according to results of a phase IIa trial presented today at the European Respiratory Society (ERS) Annual Congress in Stockholm... Forest Laboratories' Press Release -

Biomoda, Inc. and TriCore, detection of early lung cancer

Sept. 17, 2007 - Biomoda, Inc. (BMOD) of Albuquerque, NM, maker of early lung cancer detection testing and other cancer diagnostic technology, announced TriCore Reference Laboratories of Albuquerque will conduct assay preparation, testing and analysis of Biomoda's proprietary test for detection of early lung cancer as part of the company's clinical programs... Press release -

Replidyne's Phase III clinical program for the treatment of community-acquired respiratory tract infections in adults and children

Sept. 17, 2007 - Replidyne, Inc. (Nasdaq: RDYN) announced that it will be presenting 21 posters highlighting three major pipeline programs at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) held at the McCormick Place conference center in Chicago. The posters will showcase previously unpublished data related to faropenem medoxomil (faropenem), Replidyne's Phase III clinical program for the treatment of community-acquired respiratory tract infections in adults and children.. Replidyne's Press release.

Exelixis Submits XL880 Diligence Report to GlaxoSmithKline

Sept. 14, 2007- Exelixis, Inc. (Nasdaq: EXEL) announced that the company has submitted a comprehensive data report relating to XL880 to GlaxoSmithKline (GSK)...

XL880 has attractive pharmaceutical properties, with high solubility and oral bioavailability. In preclinical studies, XL880 inhibited its targets with nanomolar potency, and retained potent activity against mutationally activated forms of MET found in hereditary papillary renal cell carcinomas. The compound also demonstrated dose-dependent tumor growth inhibition in models of breast cancer, colorectal cancer, non-small cell lung cancer, and glioblastoma, and has been shown to cause substantial tumor regression in all models tested...

Exelixis' Press Release -

Genmab,Target and Development Plans for HuMax-Inflam

September 13, 2007 – Genmab A/S (OMX: GEN) announced today its fully human HuMax-Inflam™ antibody is directed to IL-8 (interleukin-8) and may have potential application in oncology and inflammation. Genmab will initially focus on studies to treat glioblastoma, a cancer of the central nervous system. Other possible indications include chronic obstructive pulmonary disease (COPD) and pustular dermatoses... Genmab's Press Release -

Illumina, Genotyping Service Agreement with Leading UK-Based Cancer Research Group

Sept. 12, 2007--Illumina, Inc. (NASDAQ:ILMN) announced that Cancer Research UK will fund two studies designed to uncover genetic factors linked to the development of lung and ovarian cancers...Illumina's Press Release -

Seegene, Diagnostic Test Kit Capable of Detecting 18 Different Virus- and Bacteria-Born Respiratory Infections in a Single Tube

September 11, 2007 - With another potentially virulent flu season approaching, Seegene introduced a breakthrough multiplex-formatted diagnostic test covering the most common virus and bacteria respiratory infections in a single reaction tube. The Seeplex® 18-plex Respiratory Test is the only diagnostic test capable of simultaneously detecting 18 of the most prevalent respiratory infections -- both virus and bacteria born -- in a single test. The Seeplex® 18-plex Respiratory Test robustly detects 11 different respiratory RNA viruses, 2 DNA viruses, and 5 pneumonia bacteria from samples including nasopharyngeal aspirates, nasopharyngeal swabs and bronchoalveolar lavage... Seegene's Press Release -

GeneGo and the Cystic Fibrosis Foundation Collaborate to Advance Understanding of Cystic Fibrosis

September 11th, 2007 — GeneGo, Inc. and the Cystic Fibrosis Foundation announced their collaboration to develop a software suite for the integration and analysis of cystic fibrosis data...MetaMiner™ (CF) will include cystic fibrosis specific OMICs and small experiments content annotated by GeneGo, disease maps and networks.... GeneGo's Press Release -

ImClone and BMS, ERBITUX ,Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study

Tuesday September 11,, 2007 - ImClone Systems Incorporated (NASDAQ: IMCL) and Bristol-Myers Squibb Company (NYSE: BMY) announced that a Phase III study of ERBITUX® (Cetuximab) in combination with platinum-based chemotherapy (vinorelbine plus cisplatin) met its primary endpoint of increasing overall survival compared with chemotherapy alone in patients with advanced non-small cell lung cancer (NSCLC)...
Bristol-Myers Squibb Company's Press Release -
ImClone Systems Incorporated's Press Release -

China Kangtai Cactus Biotech, Cactus Health Cigarettes

Sept. 10 , 2007- China Kangtai Cactus Biotech, Inc. (OTC Bulletin Board: CKGT), a vertically integrated grower, developer, manufacturer and marketer of a variety of cactus-based consumer products, announced today that the Company plans to launch a new product: Cactus Health Cigarettes... The harmful effects of cigarette smoking and the difficulty to quit smoking are well known. Cigarette production and consumption are especially high in China. Large numbers of people die every year due to traditional nicotine cigarette-related diseases, and many also suffer from illnesses related to second-hand smoke. The launch of cactus health cigarettes is a Gospel to those who suffer miserably from smoking... China Kangtai Cactus Biotech's Press Release -

Novelos Therapeutics, 5th U.S. Patent

Monday September 10, 2007 - Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, announced that Novelos was issued U.S. Pat. No. 7,169,412 by the U.S. Patent and Trademark Office extending the composition and method of use claims relating to NOV-002, Novelos' lead compound in pivotal Phase 3 trial for non-small cell lung cancer under a Special Protocol Assessment (SPA) and Fast Track... Novelos Therapeutics' Press Release -

Accuray, FDA Clearance for New Dose Calculation Technique for Body Radiosurgery

September 10, 2007 – Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced that its Monte Carlo Dose Calculation algorithm has received 510(k) clearance from the U.S. Food and Drug Administration and is now commercially available worldwide. This announcement was made as part of the product’s launch at the 9th Biennial European Society for Therapeutic Radiology and Oncology (ESTRO) meeting on Physics and Radiation Technology for Clinical Radiotherapy in Barcelona, Spain..."The clearance and commercial availability of Accuray's Monte Carlo Dose Calculation algorithm is a significant milestone in the use of radiosurgery to treat tumors anywhere in the body, particularly lung tumors" said Euan S. Thomson, Ph.D., president and CEO of Accuray... Accuray's Press Release -

TapImmune, Initiation of Testing on Novel Cancer Vaccine

September 10, 2007 - TapImmune Inc., (OTCBB: TPIM; Germany: GX1A) a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, today announced FDA compliant testing company AppTec, headquartered in St. Paul, Minnesota, has begun preclinical testing of its lead product, a TAP based therapeutic cancer vaccine. The immunotherapy vaccine is designed to treat a wide variety of TAP deficient carcinomas that include lung cancers, liver cancers, kidney cancers, head and neck cancers, breast cancers, melanomas, prostate cancers, colorectal cancers, and cervical cancers. This is the first step in the product development program that will bring the vaccine to Phase 1 Human studies... TapImmune's Press Release -

Perceptronix, Launch of LungSign(TM)

Sept. 10, 2007 - Perceptronix Announces Launch of LungSign(TM)
...LungSign^TM is a safe, painless and convenient test to assess a patient's risk of lung cancer based on an innovative marker in sputum that is highly correlated with the presence of lung malignancy - even in early stage, presymptomatic disease. As such, LungSign^TM is the first test to market that provides both an independent result to help with the early detection of lung cancer and a useful complement to current radiological diagnostic methods. LungSign^TM may benefit high-risk patients of both sexes, in particular: smokers, former smokers, and individuals exposed to industrial and environmental carcinogens. LungSign^TM is requested and interpreted under the care of a physician... Perceptronix's Press Release [PDF] -

TOPIGEN Pharmaceuticals, TPI 1020 Into Phase 2 Development for COPD

September 10, 2007 - TOPIGEN Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company specializing in respiratory disorders, announced the successful completion of a Phase 2a safety trial with TPI 1020 in smokers with asthma.
TOPIGEN also announced plans to initiate a Phase 2 clinical trial of TPI 1020 in chronic obstructive pulmonary disease (COPD) in the second half of 2007.TPI 1020 is a novel anti-inflammatory respiratory drug licensed from NicOx S.A.

TOPIGEN Pharmaceuticals' Press Release -

NicOx's Press Release (PDF English) -

Communiqué de Presse NicOx en Français [PDF] -

OSI Pharmaceuticals, Data Presented on Tarceva(R) (erlotinib) at the 12th World Congress on Lung Cancer Meeting

Sep 07, 2007 - OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) provided a summary of selected data from over 58 studies involving the Company's lead product, Tarceva(R), presented during the 12th World Congress on Lung Cancer (WCLC) held September 2-6 in Seoul, Korea. Tarceva is currently approved in the United States as monotherapy for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen, and in combination with gemcitabine chemotherapy for the first-line treatment of locally advanced, unresectable, or metastatic pancreatic cancer... OSI Pharmaceuticals' Press Releases -

superDimension, First Device to Enable Minimally-Invasive Access to Distant Areas of Lungs

Sept. 5, 2007 – The first device to allow physicians to access smaller, harder-to-reach lung lesions has received 510(k) clearance from the Food and Drug Administration (FDA). The inReach^TM System, developed by Minneapolis-based superDimension, provides electromagnetic navigation and guidance to distant regions of the lungs in a minimally-invasive manner, enabling doctors to diagnose lung cancer at earlier stages and potentially provide treatment sooner... Read superDimension's Press Release -

Aradigm and CyDex, Development Collaboration Agreement for the treatment of asthma and chronic obstructive pulmonary diseases (COPD).

September 6, 2007 - Aradigm Corporation (OTCBB:ARDM) and CyDex, Inc. ("CyDex") have entered into a two-year Collaboration Agreement for the development and commercialization of combination products containing inhaled corticosteroids, anticholinergics and beta-2 agonists for the treatment of asthma and chronic obstructive pulmonary diseases (COPD)... Press Release -

Amgen , Aranesp(R) Study Showing No Negative Impact on Survival in SCLC Presented at World Conference on Lung Cancer

Sept. 6, 2007--Amgen (NASDAQ:AMGN) presented the results from a randomized, double-blind, placebo-controlled Phase 3 study evaluating the efficacy and safety of Aranesp(R) (darbepoetin alfa) in previously untreated patients with extensive-stage small-cell lung cancer (SCLC) receiving chemotherapy ("the 145 study") on Monday, Sept. 3 at the 2007 World Conference on Lung Cancer in Seoul, Korea. Amgen's Press Release -

Idera Pharmaceuticals, Phase 1 Study Evaluating

September 6, 2007 – Idera Pharmaceuticals, Inc. (AMEX: IDP), today announced interim results from a Phase 1 clinical trial being conducted by the Company evaluating IMO-2055, the Company’s lead Toll-Like Receptor (TLR) 9 agonist, in combination with gemcitabine and carboplatin in patients with advanced solid tumors......The data presented in the poster concern 19 patients evaluated for safety and also for efficacy prior to June 2007, including eight patients with non-small cell lung cancer (NSCLC)...
[PDF] Idera Pharmaceuticals' Press Release -

Introgen Therapeutics, Immunotherapy Drug [p53] Candidate to Advance Into Second Phase 2 Clinical Trial in Small Cell Lung Cancer

Sept. 6, 2007--Introgen Therapeutics, Inc. (NASDAQ:INGN) and Moffitt Cancer Center announced plans to begin a phase 2 randomized, controlled study of INGN 225, Introgen's investigational immunotherapy product in patients with metastatic small-cell lung cancer (termed extensive stage SCLC)... Introgen Therapeutics' Press Relase -

Pharmacyclics , Phase 2 Data With Xcytrin(R) in Recurrent Non-Small Cell Lung Cancer

Sept. 5, 2007 - Pharmacyclics, Inc. (Nasdaq: PCYC) today announced results from three open-label, multi-center Phase 2 clinical trials evaluating Xcytrin® (motexafin gadolinium) Injection, the company's lead product candidate, as a single-agent and in combination with chemotherapy as a second-line treatment for patients with non-small cell lung cancer (NSCLC) who failed at least one platinum-based chemotherapy regimen... Read the Pharmacyclics' Press Release -

Biomira Inc., Stimuvax(R) Phase II data highlight, non-small cell lung cancer

Sept. 5, 2007- Biomira Inc. (Nasdaq: BIOM) (TSX: BRA) : presentation of three-year survival results from a randomized Phase II trial of the Stimuvax(R) MUC-1 vaccine in non-small cell lung cancer (NSCLC)... Biomira's Press Release -

Nabi Biopharmaceuticals, Positive NicVAX (Nicotine Addiction) Phase 2b Data at Nine Months

Sept. 5 , 2007 - Nabi Biopharmaceuticals (Nasdaq: NABI) today announced nine-month data from its ongoing trial of NicVAX(R) (Nicotine Conjugate Vaccine), the company's innovative and proprietary investigational vaccine being developed to treat nicotine addiction and prevent smoking relapse... Read the Nabi Biopharmaceuticals' Press Release. -